Development of autoimmunity in lymphoma

References

• Smedby KE, Baecklund E, Askling J. Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics. Cancer Epidemiol. Biomarkers Prev.15(11), 2069–2077 (2006).
   PubMed Web of Science ®Google Scholar
• Allen CM, Camisa C. Paraneoplastic pemphigus: a review of the literature. Oral Dis.6(4), 208–214 (2000).
   PubMed Web of Science ®Google Scholar
• Ahmed AR, Avram MM, Duncan LM. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 23-2003. A 79-year-old woman with gastric lymphoma and erosive mucosal and cutaneous lesions. N. Engl. J. Med.349(4), 382–391 (2003).
   PubMed Web of Science ®Google Scholar
• Rossum MM, Verhaegen NT, Jonkman MF et al. Follicular non-Hodgkin’s lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk. Lymphoma45(11), 2327–2332 (2004).
   PubMed Web of Science ®Google Scholar
• Billet SE, Grando SA, Pittelkow MR. Paraneoplastic autoimmune multiorgan syndrome: review of the literature and support for a cytotoxic role in pathogenesis. Autoimmunity39(7), 617–630 (2006).
   PubMed Web of Science ®Google Scholar
• Hutson TE, Hoffman GS. Temporal concurrence of vasculitis and cancer: a report of 12 cases. Arthritis Care Res.13(6), 417–423 (2000).
   PubMed Web of Science ®Google Scholar
• Farrell AM, Stern SC, El-Ghariani K et al. Splenic lymphoma with villous lymphocytes presenting as leucocytoclastic vasculitis. Clin. Exp. Dermatol.24(1), 19–22 (1999).
   PubMed Web of Science ®Google Scholar
• Pavlidis NA, Klouvas G, Tsokos M, Bai M, Moutsopoulos HM. Cutaneous lymphocytic vasculopathy in lymphoproliferative disorders – a paraneoplastic lymphocytic vasculitis of the skin. Leuk. Lymphoma16(5–6), 477–482 (1995).
   PubMed Web of Science ®Google Scholar
• Hamidou MA, El Kouri D, Audrain M, Grolleau JY. Systemic antineutrophil cytoplasmic antibody vasculitis associated with lymphoid neoplasia. Ann. Rheum. Dis.60(3), 293–295 (2001).
   PubMed Web of Science ®Google Scholar
• Auzerie V, Chiali A, Bussel A et al. Leg ulcers associated with cryoglobulinemia: clinical study of 15 patients and response to treatment. Arch. Dermatol.139(3), 391–393 (2003).
   PubMedGoogle Scholar
• Fain O, Guillevin L, Kaplan G et al. [Vasculitis and neoplasms. 14 cases]. Ann. Med. Interne (Paris)142(7), 486–504 (1991).
   PubMedGoogle Scholar
• Manganelli P, Ferraccioli G, Passalacqua R, Quaini F. [Polymyalgia rheumatica and malignant neoplasms. A report of 3 cases]. Recenti Prog. Med.83(4), 200–202 (1992).
   PubMedGoogle Scholar
• Montanaro M, Bizzarri F. Non-Hodgkin’s lymphoma and subsequent acute lymphoblastic leukaemia in a patient with polymyalgia rheumatica. Br. J. Rheumatol.31(4), 277–278 (1992).
   PubMedGoogle Scholar
• Bachmeyer C, Blum L, Chesneau AM et al. Raynaud’s phenomenon with necrosis of the extremities induced by cold agglutinin disease secondary to a T-cell lymphoma. Acta Derm. Venereol.83(5), 374–375 (2003).
   PubMed Web of Science ®Google Scholar
• Stavem P, Rorvik T, Brandtzaeg P et al. Gastric lymphoma causing granulocytopenia and cold intolerance, with recovery after treatment. J. Intern. Med.229(2), 193–196 (1991).
   PubMed Web of Science ®Google Scholar
• Lauchli S, Widmer L, Lautenschlager S. Cold agglutinin disease – the importance of cutaneous signs. Dermatology202(4), 356–358 (2001).
   PubMed Web of Science ®Google Scholar
• Foti R, Fazio P, Lizzio G, Leonardi R. [Angioedema: first manifestation of non-Hodgkin’s lymphoma]. Ann. Ital. Med. Int.17(3), 185–188 (2002).
   PubMedGoogle Scholar
• Castelli R, Deliliers DL, Zingale LC, Pogliani EM, Cicardi M. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica92(5), 716–718 (2007).
   PubMed Web of Science ®Google Scholar
• Woodrow SL, Munn SE, Basarab T, Russel Jones R. Sweet’s syndrome in association with non-Hodgkin’s lymphoma. Clin. Exp. Dermatol.21(5), 357–359 (1996).
   PubMed Web of Science ®Google Scholar
• Callen JP. Pyoderma gangrenosum. Lancet351(9102), 581–585 (1998).
   PubMed Web of Science ®Google Scholar
• Futei Y, Konohana I. A case of erythema elevatum diutinum associated with B-cell lymphoma: a rare distribution involving palms, soles and nails. Br. J. Dermatol.142(1), 116–119 (2000).
   PubMed Web of Science ®Google Scholar
• Alonso-Llamazares J, Gibson LE, Rogers RS 3rd. Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience. Int. J. Dermatol.46(9), 910–919 (2007).
   PubMed Web of Science ®Google Scholar
• Ropper AH, Gorson KC. Neuropathies associated with paraproteinemia. N. Engl. J. Med.338(22), 1601–1607 (1998).
   PubMed Web of Science ®Google Scholar
• Noguchi M, Mori K, Yamazaki S et al. Multifocal motor neuropathy caused by a B-cell lymphoma producing a monoclonal IgM autoantibody against peripheral nerve myelin glycolipids GM1 and GD1b. Br. J. Haematol.123(4), 600–605 (2003).
   PubMed Web of Science ®Google Scholar
• Donfrid M, Apostolski S, Suvajdzic N et al. Monocytoid B cell lymphoma associated with antibodies to myelin-associated glycoprotein and sulphated glucuronyl paragloboside. Acta Haematol.106(3), 130–132 (2001).
   PubMed Web of Science ®Google Scholar
• Mallecourt C, Delattre JY. Neuropathies paranéoplasiques. Presse Med.29(8), 447–452 (2000).
   PubMed Web of Science ®Google Scholar
• Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology50(3), 652–657 (1998).
   PubMed Web of Science ®Google Scholar
• Re D, Schwenk A, Hegener P et al. Guillain–Barre syndrome in a patient with non-Hodgkin’s lymphoma. Ann. Oncol.11(2), 217–220 (2000).
   PubMed Web of Science ®Google Scholar
• Mudad R, Hussein A, Peters WP. Guillain–Barre syndrome following autologous bone marrow transplantation. Am. J. Clin. Oncol.18(2), 167–169 (1995).
   PubMed Web of Science ®Google Scholar
• Vallat JM, De Mascarel HA, Bordessoule D et al. Non-Hodgkin malignant lymphomas and peripheral neuropathies – 13 cases. Brain118(Pt 5), 1233–1245 (1995).
   PubMed Web of Science ®Google Scholar
• Sillevis Smitt P, Kinoshita A, De Leeuw B et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N. Engl. J. Med.342(1), 21–27 (2000).
   PubMed Web of Science ®Google Scholar
• Ducrocq X, Petit J, Taillandier L et al. Syndrome opsoclonus–myoclonus paranéoplasique révélateur d’un lymphome T. Presse Med.28(7), 330–333 (1999).
   PubMed Web of Science ®Google Scholar
• Argov Z, Shapira Y, Averbuch-Heller L, Wirguin I. Lambert–Eaton myasthenic syndrome (LEMS) in association with lymphoproliferative disorders. Muscle Nerve18(7), 715–719 (1995).
   PubMed Web of Science ®Google Scholar
• Ferro MT, Riccardi T, Montanelli A, Bernasconi P, Mantegazza R. Myasthenia gravis remission and anti-AChR ab reduction after immunosuppressive and anti-neoplastic therapy in a patient with thymic Hodgkin’s disease. J. Neurol.253(9), 1241–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Mortimer JE, Kidd P. Myasthenia gravis and lymphoblastic lymphoma antiacetylcholine receptor antibody as a tumor marker – a case report. Cancer Invest.7(4), 327–331 (1989).
   PubMed Web of Science ®Google Scholar
• Rosen CL, DePalma L, Morita A. Primary angiitis of the central nervous system as a first presentation in Hodgkin’s disease: a case report and review of the literature. Neurosurgery46(6), 1504–1508 (2000).
   PubMed Web of Science ®Google Scholar
• Jardin F, Callonnec F, Contentin N et al. Intravascular large B-cell lymphoma with bone marrow involvement and superior sagittal sinus thrombosis: report of a case successfully treated with a CHOP/rituximab combination regimen. Clin. Lymphoma6(1), 46–49 (2005).
   PubMedGoogle Scholar
• Hashida N, Kanayama S, Kawasaki A, Ogawa K. A case of Vogt–Koyanagi–Harada disease associated with malignant lymphoma. Jpn. J. Ophthalmol.49(3), 253–256 (2005).
   PubMed Web of Science ®Google Scholar
• Damico FM, Kiss S, Young LH. Vogt–Koyanagi–Harada disease. Semin. Ophthalmol.20(3), 183–190 (2005).
   PubMedGoogle Scholar
• To KW, Thirkill CE, Jakobiec FA, Lessell S, Berson EL. Lymphoma-associated retinopathy. Ophthalmology109(11), 2149–2153 (2002).
   PubMed Web of Science ®Google Scholar
• Genty I, Michel M, Hermine O et al. Caractéristiques des anémies hémolytiques de l’adulte: analyse rétrospective de 83 cas. Rev. Med. Interne23(11), 901–909 (2002).
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY, Hanrahan LR. Future development of lymphoproliferative disorders in patients with autoimmune hemolytic anemia in 107 patients. Clin. Cancer Res.7(4), 791–794 (2001).
   PubMed Web of Science ®Google Scholar
• Xiros N, Binder T, Anger B, Bohlke J, Heimpel H. Idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia in Hodgkin’s disease. Eur. J. Haematol.40(5), 437–441 (1988).
   PubMed Web of Science ®Google Scholar
• Hauswirth AW, Skrabs C, Schutzinger C et al. Autoimmune hemolytic anemias, Evans’ syndromes, and pure red cell aplasia in non-Hodgkin lymphomas. Leuk. Lymphoma48(6), 1139–1149 (2007).
   PubMed Web of Science ®Google Scholar
• Sallah S, Sigounas G, Vos P, Wan JY, Nguyen NP. Autoimmune hemolytic anemia in patients with non-Hodgkin’s lymphoma: characteristics and significance. Ann. Oncol.11(12), 1571–1577 (2000).
   PubMed Web of Science ®Google Scholar
• Crisp D, Pruzanski W. B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins). Am. J. Med.72(6), 915–922 (1982).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Bo K, Shammas FV, Myking AO, Ulvestad E. Chronic cold agglutinin disease of the ‘idiopathic’ type is a premalignant or low-grade malignant lymphoproliferative disease. APMIS105(5), 354–362 (1997).
   PubMed Web of Science ®Google Scholar
• Berentsen S, Ulvestad E, Langholm R et al. Primary chronic cold agglutinin disease: a population based clinical study of 86 patients. Haematologica91(4), 460–466 (2006).
   PubMed Web of Science ®Google Scholar
• Sivakumaran M, Murphy PT, Booker DJ et al. Paroxysmal cold haemoglobinuria caused by non-Hodgkin’s lymphoma. Br. J. Haematol.105(1), 278–279 (1999).
   PubMed Web of Science ®Google Scholar
• Zeidman A, Fradin Z, Barac Y et al. Splenic lymphoma presenting as warm autoimmune hemolytic anemia associated with pure red cell aplasia. Vox Sang.78(2), 126–129 (2000).
   PubMed Web of Science ®Google Scholar
• Barrios Y, Plaza A, Cabrera R, Diaz-Espada F. Autoantibody activity of the immunoglobulin secreted by a follicular B-cell lymphoma. APMIS108(11), 764–770 (2000).
   PubMed Web of Science ®Google Scholar
• Jones SE. Autoimmune disorders and malignant lymphoma. Cancer31(5), 1092–1098 (1973).
   PubMed Web of Science ®Google Scholar
• Bachmeyer C, Audouin J, Bouillot JL et al. Immune thrombocytopenic purpura as the presenting feature of gastric MALT lymphoma. Am. J. Gastroenterol.95(6), 1599–1600 (2000).
   PubMed Web of Science ®Google Scholar
• Garderet L, Aoudjhane M, Bonte H et al. Immune thrombocytopenic purpura: first symptom of g/d T-cell lymphoma. Am. J. Med.111(3), 242–243 (2001).
   PubMed Web of Science ®Google Scholar
• Kubota T, Tanoue K, Murohashi I et al. Autoantibody against platelet glycoprotein IIb/IIIa in a patient with non-Hodgkin’s lymphoma. Thromb. Res.53(4), 379–386 (1989).
   PubMed Web of Science ®Google Scholar
• Uesugi Y, Fuse I, Toba K, Koike T, Shibata A. Acquired immune thrombocytopenia caused by IgG antiglycoprotein Ib antibody in a patient with Hodgkin’s disease. Acta Haematol.98(4), 217–220 (1997).
   PubMed Web of Science ®Google Scholar
• Nobuoka A, Sakamaki S, Kogawa K et al. A case of malignant lymphoma producing autoantibody against platelet glycoprotein Ib. Int. J. Hematol.70(3), 200–206 (1999).
   PubMed Web of Science ®Google Scholar
• Malik U, Dutcher JP, Oleksowicz L. Acquired Glanzmann’s thrombasthenia associated with Hodgkin’s lymphoma: a case report and review of the literature. Cancer82(9), 1764–1768 (1998).
   PubMed Web of Science ®Google Scholar
• Greer JP, Kinney MC, Loughran TP Jr. T cell and NK cell lymphoproliferative disorders. Hematology Am. Soc. Hematol. Educ. Program259–281 (2001).
   PubMedGoogle Scholar
• Lamy T. Neutropénies autoimmunes. Rev. Prat.51(14), 1552–1557 (2001).
   PubMedGoogle Scholar
• Cartron J, Fior R, Boue F et al. Non Hodgkin’s lymphoma presenting as neutropenia related to an IgM monoclonal anti-i antibody. Hematol. Cell Ther.38(2), 225–230 (1996).
   PubMedGoogle Scholar
• Gupta V, Eden AJ, Mills MJ. Helicobacter pylori and autoimmune neutropenia. Clin. Lab. Haematol.24(3), 183–185 (2002).
   PubMedGoogle Scholar
• Lee ES, Hibsman BK, Liebman HA. Acquired bleeding disorder in a patient with malignant lymphoma: antibody-mediated prothrombin deficiency. Cancer91(4), 636–641 (2001).
   PubMed Web of Science ®Google Scholar
• Sallah S, Wan JY. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients. Cancer91(6), 1067–1074 (2001).
   PubMed Web of Science ®Google Scholar
• Mody GM, Cassim B. Rheumatologic manifestations of malignancy. Curr. Opin. Rheumatol.9(1), 75–79 (1997).
   PubMedGoogle Scholar
• Conaghan PG, Brooks PM. Rheumatic manifestations of malignancy. Curr. Opin. Rheumatol.6(1), 105–110 (1994).
   PubMedGoogle Scholar
• Naschitz JE, Rosner I, Rozenbaum M, Zuckerman E, Yeshurun D. Rheumatic syndromes: clues to occult neoplasia. Semin. Arthritis Rheum.29(1), 43–55 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen MR, Carrera GE, Lundberg J. Rapidly progressive sacroiliitis in a patient with lymphocytic lymphoma. Ann. Rheum. Dis.52(3), 239–240 (1993).
   PubMed Web of Science ®Google Scholar
• Daneshpouy M, Bataille D, Rivet J et al. Peripheral T-cell lymphoma with eosinophilia presenting as monoarthritis: a case study. Leuk. Lymphoma43(9), 1875–1879 (2002).
   PubMed Web of Science ®Google Scholar
• Gisserot O, Cremades S, Landais C et al. RS3PE revealing recurrent non-Hodgkin’s lymphoma. Joint Bone Spine.71(5), 424–426 (2004).
   PubMed Web of Science ®Google Scholar
• Russell EB. Remitting seronegative symmetrical synovitis with pitting edema syndrome: followup for neoplasia. J. Rheumatol.32(9), 1760–1761 (2005).
   PubMed Web of Science ®Google Scholar
• Trotta F, Dovigo L, Scapoli G, Cavazzini L, Castoldi G. Immunoblastic malignant lymphoma in adult onset Still’s disease. J. Rheumatol.20(10), 1788–1792 (1993).
   PubMed Web of Science ®Google Scholar
• Sono H, Matsuo K, Miyazato H et al. A case of adult-onset Still’s disease complicated by non-Hodgkin’s lymphoma. Lupus9(6), 468–470 (2000).
   PubMed Web of Science ®Google Scholar
• Kawasaki T, Hirohata S, Hashimoto T, Miyashita H, Tanaka F. T cell lymphoma masquerading as adult onset Still’s disease. Clin. Exp. Rheumatol.13(3), 410–411 (1995).
   PubMed Web of Science ®Google Scholar
• Naschitz JE, Yeshurun D, Zuckerman E et al. Cancer-associated fasciitis panniculitis. Cancer73(1), 231–235 (1994).
   PubMed Web of Science ®Google Scholar
• Hasegawa M, Sato S, Sakai H, Ohashi T, Takehara K. Systemic sclerosis revealing T-cell lymphoma. Dermatology198(1), 75–78 (1999).
   PubMed Web of Science ®Google Scholar
• Polliack A, Lugassy G. Autoimmunity and auto-immune syndromes associated with and preceding the development of lymphoproliferative disorders. Leukemia6(Suppl. 4), 152–154 (1992).
   PubMed Web of Science ®Google Scholar
• Hill CL, Zhang Y, Sigurgeirsson B et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet357(9250), 96–100 (2001).
   PubMed Web of Science ®Google Scholar
• Ferri C, La Civita L, Longombardo G, Zignego AL, Pasero G. Mixed cryoglobulinaemia: a cross-road between autoimmune and lymphoproliferative disorders. Lupus7(4), 275–279 (1998).
   PubMed Web of Science ®Google Scholar
• Trejo O, Ramos-Casals M, Lopez-Guillermo A et al. Hematologic malignancies in patients with cryoglobulinemia: association with autoimmune and chronic viral diseases. Semin. Arthritis Rheum.33(1), 19–28 (2003).
   PubMed Web of Science ®Google Scholar
• Saadoun D, Landau DA, Calabrese LH, Cacoub PP. Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation. Rheumatology (Oxford). (2007).
   Google Scholar
• Da’as N, Polliack A, Cohen Y et al. Kidney involvement and renal manifestations in non-Hodgkin’s lymphoma and lymphocytic leukemia: a retrospective study in 700 patients. Eur. J. Haematol.67(3), 158–164 (2001).
   PubMed Web of Science ®Google Scholar
• Evans DJ, Macanovic M, Dunn MJ, Pusey CD. Membranous glomerulonephritis associated with follicular B-cell lymphoma and subepithelial deposition of IgG1-k paraprotein. Nephron. Clin. Pract.93(3), c112–118 (2003).
   Google Scholar
• Stokes MB, Wood B, Alpers ChE. Membranoproliferative glomerulonephritis associated with low-grade B cell lymphoma presenting in the kidney. Clin. Nephrol.57(4), 303–309 (2002).
   PubMed Web of Science ®Google Scholar
• Pertuiset E, Liote F, Launay-Russ E et al. Adult Henoch–Schonlein purpura associated with malignancy. Semin. Arthritis Rheum.29(6), 360–367 (2000).
   PubMed Web of Science ®Google Scholar
• Guyomard S, Salles G, Coudurier M et al. Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin’s lymphoma. Br. J. Haematol.123(1), 90–99 (2003).
   PubMed Web of Science ®Google Scholar
• Swissa M, Cohen Y, Shoenfeld Y. Autoantibodies in the sera of patients with lymphoma. Leuk. Lymphoma7(1–2), 117–122 (1992).
   PubMed Web of Science ®Google Scholar
• Timuragaoglu A, Duman A, Ongut G, Saka O, Karadogan I. The significance of autoantibodies in non-Hodgkin’s lymphoma. Leuk. Lymphoma40(1–2), 119–122 (2000).
   PubMed Web of Science ®Google Scholar
• Chloraki-Bobota A, Megalakaki C, Repousis P et al. Prevalence of autoantibodies (ANA, anti ds-DNA, ENA, IMF) and rheumatic syndromes in patients with lymphoproliferative diseases. J. Buon.11(4), 485–489 (2006).
   PubMedGoogle Scholar
• Peterson SR, Talpur R, Duvic M. Antinuclear antibody seropositivity in patients with cutaneous T-cell lymphoma. J. Am. Acad. Dermatol.39(3), 434–438 (1998).
   PubMed Web of Science ®Google Scholar
• Finazzi G, Brancaccio V, Moia M et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am. J. Med.100(5), 530–536 (1996).
   PubMed Web of Science ®Google Scholar
• Schved JF, Dupuy-Fons C, Biron C, Quere I, Janbon C. A prospective epidemiological study on the occurrence of antiphospholipid antibody: the Montpellier Antiphospholipid (MAP) Study. Haemostasis24(3), 175–182 (1994).
   PubMedGoogle Scholar
• Sawamura M, Yamaguchi S, Murakami H et al. Multiple autoantibody production in a patient with splenic lymphoma. Ann. Hematol.68(5), 251–254 (1994).
   PubMed Web of Science ®Google Scholar
• Gallart T, Benito C, Reverter JC et al. True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. Br. J. Haematol.116(4), 875–886 (2002).
   PubMed Web of Science ®Google Scholar
• Sciarra A, Stasi R, Stipa E et al. [Antiphospholipid antibodies: their prevalence, clinical significance and correlation with cytokine levels in acute myeloid leukemia and non-Hodgkin’s lymphoma]. Recenti Prog. Med.86(2), 57–62 (1995).
   PubMedGoogle Scholar
• Genvresse I, Luftner D, Spath-Schwalbe E, Buttgereit F. Prevalence and clinical significance of anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma. Eur. J. Haematol.68(2), 84–90 (2002).
   PubMed Web of Science ®Google Scholar
• Bairey O, Blickstein D, Monselise Y et al. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin’s lymphoma. Eur. J. Haematol.76(5), 384–391 (2006).
   PubMed Web of Science ®Google Scholar
• Genvresse I, Buttgereit F, Spath-Schwalbe E et al. Arterial thrombosis associated with anticardiolipin and anti-β2-glycoprotein-I antibodies in patients with non-Hodgkin’s lymphoma: a report of two cases. Eur. J. Haematol.65(5), 344–347 (2000).
   PubMed Web of Science ®Google Scholar
• Shaw BE, Perry D, Hoffbrand AV. Progressive arterial thrombosis in a patient with non-Hodgkin’s lymphoma, a lupus anticoagulant, factor V Leiden mutation and paraprotein, following chemotherapy. Leuk. Lymphoma42(1–2), 221–223 (2001).
   PubMed Web of Science ®Google Scholar
• McGuire D, Zeidman A, Mittelman M. Non-Hodgkin’s lymphoma presenting with coagulopathy due to anti-phospholipid antibody syndrome. Leuk. Lymphoma26(1–2), 193–196 (1997).
   PubMed Web of Science ®Google Scholar
• Hill VA, Whittaker SJ, Hunt BJ et al. Cutaneous necrosis associated with the antiphospholipid syndrome and mycosis fungoides. Br. J. Dermatol.130(1), 92–96 (1994).
   PubMed Web of Science ®Google Scholar
• Andrejevic S, Bonaci-Nikolic B, Bukilica M et al. Purpura and leg ulcers in a patient with cryoglobulinaemia, non-Hodgkin’s lymphoma, and antiphospholipid syndrome. Clin. Exp. Dermatol.28(2), 151–153 (2003).
   PubMed Web of Science ®Google Scholar
• Carroccio A, Iannitto E, Di Prima L et al. Screening for celiac disease in non-Hodgkin’s lymphoma patients: a serum anti-transglutaminase-based approach. Dig. Dis. Sci.48(8), 1530–1536 (2003).
   PubMed Web of Science ®Google Scholar
• Carroccio A, Fabiani E, Iannitto E et al. Tissue transglutaminase autoantibodies in patients with non-Hodgkin’s lymphoma. Case reports. Digestion62(4), 271–275 (2000).
   Google Scholar
• Kourtis AP, Boussiotis VA, Lymberi P, Pangalis GA. Increased natural antibody activity in sera of patients with malignant non-Hodgkin’s lymphomas containing paraproteins. Am. J. Hematol.46(4), 283–288 (1994).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Mayer A, Dumontet C et al. Primary thyroid lymphoma is a heterogeneous disease. J. Clin. Endocrinol. Metab.87(1), 105–111 (2002).
   PubMed Web of Science ®Google Scholar
• Hamidou MA, Derenne S, Audrain MA et al. Prevalence of rheumatic manifestations and antineutrophil cytoplasmic antibodies in haematological malignancies. A prospective study. Rheumatology (Oxford)39(4), 417–420 (2000).
   PubMed Web of Science ®Google Scholar
• Adamson PJ, Zola H, Nicholson IC, Pilkington G, Hohmann A. Antibody against CD20 in patients with B cell malignancy. Leuk. Res.25(12), 1047–1050 (2001).
   PubMed Web of Science ®Google Scholar
• Van Den Neste E, Delannoy A, Feremans W, Ferrant A, Michaux L. Second primary tumors and immune phenomena after fludarabine or 2-chloro-2´-deoxyadenosine treatment. Leuk. Lymphoma40(5–6), 541–550 (2001).
   PubMed Web of Science ®Google Scholar
• Churn M, Clough V. Autoimmune thrombocytopenia associated with the first cycle of fludarabine therapy in the treatment of relapsed non-Hodgkin’s lymphoma. Clin. Oncol. (R. Coll. Radiol.)13(4), 273–275 (2001).
   PubMed Web of Science ®Google Scholar
• Braess J, Reich K, Willert S et al. Mucocutaneous autoimmune syndrome following fludarabine therapy for low-grade non-Hodgkin’s lymphoma of B-cell type (B-NHL). Ann. Hematol.75(5–6), 227–230 (1997).
   PubMed Web of Science ®Google Scholar
• Paydas S, Sahin B, Hazar B, Yavuz S. The association of thyrotoxicosis and chronic lymphoproliferative disorders. Leuk. Lymphoma38(1–2), 131–135 (2000).
   PubMed Web of Science ®Google Scholar
• Au WY, Lie AK, Kung AW et al. Autoimmune thyroid dysfunction after hematopoietic stem cell transplantation. Bone Marrow Transplant.35(4), 383–388 (2005).
   PubMed Web of Science ®Google Scholar
• Illes A, Biro E, Miltenyi Z et al. Hypothyroidism and thyroiditis after therapy for Hodgkin’s disease. Acta Haematol.109(1), 11–17 (2003).
   PubMed Web of Science ®Google Scholar
• Ishikawa F, Shigematsu H, Gondo H, Okamura T, Niho Y. Autoreactive antibodies following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant.22(7), 729–731 (1998).
   PubMed Web of Science ®Google Scholar
• Keung YK, Cobos E, Bolanos-Meade J et al. Evans syndrome after autologous bone marrow transplant for recurrent Hodgkin’s disease. Bone Marrow Transplant.20(12), 1099–1101 (1997).
   PubMed Web of Science ®Google Scholar
• Imamura R, Inoue H, Kato K et al. Development of rheumatoid arthritis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant.30(8), 527–529 (2002).
   PubMed Web of Science ®Google Scholar
• Hequet O, Salles G, Ketterer N et al. Autoimmune thrombocytopenic purpura after autologous stem cell transplantation. Bone Marrow Transplant.32(1), 89–95 (2003).
   PubMed Web of Science ®Google Scholar
• Jillella AP, Kallab AM, Kutlar A. Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Bone Marrow Transplant.26(8), 925–927 (2000).
   PubMed Web of Science ®Google Scholar
• Sivakumaran M, Hutchinson RM, Pringle H et al. Thrombocytopenia following autologous bone marrow transplantation: evidence for autoimmune aetiology and B cell clonal involvement. Bone Marrow Transplant.15(4), 531–536 (1995).
   PubMed Web of Science ®Google Scholar
• Isobe T, Tanimoto TE, Nakaji G et al. Autoimmune thrombocytopenia with clonal expansion of CD8-positive T cells after autologous peripheral blood stem cell transplantation for diffuse large B-cell lymphoma. Bone Marrow Transplant.35(3), 315–316 (2005).
   PubMed Web of Science ®Google Scholar
• Sanmarco M, Vialettes B, Maraninchi D, Bernard D. Autoantibody formation after bone marrow transplantation: a comparison between autologous and allogeneic grafts. Autoimmunity11(1), 7–12 (1991).
   PubMed Web of Science ®Google Scholar
• Chan EY, Lawton JW, Lie AK, Lau CS. Autoantibody formation after allogeneic bone marrow transplantation: correlation with the reconstitution of CD+ B cells and occurrence of graft-versus-host disease. Pathology29(2), 184–188 (1997).
   PubMed Web of Science ®Google Scholar
• Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N. Engl. J. Med.348(26), 2691–2694 (2003).
   PubMed Web of Science ®Google Scholar
• Chaiwatanatorn K, Lee N, Grigg A, Filshie R, Firkin F. Delayed-onset neutropenia associated with rituximab therapy. Br. J. Haematol.121(6), 913–918 (2003).
   PubMed Web of Science ®Google Scholar
• Larrar S, Guitton C, Willems M, Bader-Meunier B. Severe hematological side effects following rituximab therapy in children. Haematologica91(8 Suppl.), ECR36 (2006).
   PubMedGoogle Scholar
• Otrock ZK, Mahfouz RA, Oghlakian GO, Salem ZM, Bazarbachi A. Rituximab-induced acute thrombocytopenia: a report of two cases. Haematologica90(Suppl.), ECR23 (2005).
   PubMedGoogle Scholar
• Nitta E, Izutsu K, Sato T et al. A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study. Ann. Oncol.18(2), 364–369 (2007).
   PubMed Web of Science ®Google Scholar
• Lemieux B, Tartas S, Traulle C et al. Rituximab-related late-onset neutropenia after autologous stem cell transplantation for aggressive non-Hodgkin’s lymphoma. Bone Marrow Transplant.33(9), 921–923 (2004).
   PubMed Web of Science ®Google Scholar
• Cairoli R, Grillo G, Tedeschi A et al. High incidence of neutropenia in patients treated with rituximab after autologous stem cell transplantation. Haematologica89(3), 361–363 (2004).
   PubMed Web of Science ®Google Scholar
• Jourdan E, Topart D, Richard B, Jourdan J, Sotto A. Severe autoimmune hemolytic anemia following rituximab therapy in a patient with a lymphoproliferative disorder. Leuk. Lymphoma44(5), 889–890 (2003).
   PubMed Web of Science ®Google Scholar
• Papadaki T, Stamatopoulos K, Kosmas C et al. Clonal T-large granular lymphocyte proliferations associated with clonal B cell lymphoproliferative disorders: report of eight cases. Leukemia16(10), 2167–2169 (2002).
   PubMed Web of Science ®Google Scholar
• Terrier B, Ittah M, Tourneur L et al. Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica92(3 Suppl.), ECR10 (2007).
   Google Scholar
• Varoczy L, Gergely L, Zeher M, Szegedi G, Illes A. Malignant lymphoma-associated autoimmune diseases – a descriptive epidemiological study. Rheumatol. Int.22(6), 233–237 (2002).
   PubMed Web of Science ®Google Scholar
• Jonsson V, Wiik A, Hou-Jensen K et al. Autoimmunity and extranodal lymphocytic infiltrates in lymphoproliferative disorders. J. Intern. Med.245(3), 277–286 (1999).
   PubMed Web of Science ®Google Scholar
• Dighiero G, Hart S, Lim A et al. Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood78(3), 581–585 (1991).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Berger F et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin. Lymphoma3(1), 41–47 (2002).
   PubMedGoogle Scholar
• Murakami H, Irisawa H, Saitoh T et al. Immunological abnormalities in splenic marginal zone cell lymphoma. Am. J. Hematol.56(3), 173–178 (1997).
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Felman P, Callet-Bauchu E et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol.4(2), 95–103 (2003).
   PubMed Web of Science ®Google Scholar
• Eck M, Schmausser B, Kerkau T et al. Autoantibodies in gastric MALT-type lymphoma. Ann. Oncol.14(7), 1153–1154 (2003).
   PubMed Web of Science ®Google Scholar
• Wohrer S, Troch M, Streubel B et al. MALT lymphoma in patients with autoimmune diseases: a comparative analysis of characteristics and clinical course. Leukemia21(8), 1812–1818 (2007).
   PubMed Web of Science ®Google Scholar
• Kawahara Y, Yokota K, Mizuno M et al. Antibodies to human gastric epithelial cells and heat shock protein 60 in Helicobacter pylori positive mucosa associated lymphoid tissue lymphoma. Gut45(1), 20–23 (1999).
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, Sfikakis P, Dalakas M. Waldenstrom’s macroglobulinemia: clinical features, complications, and management. J. Clin. Oncol.18(1), 214–226 (2000).
   PubMed Web of Science ®Google Scholar
• Jonsson V, Kierkegaard A, Salling S et al. Autoimmunity in Waldenstrom’s macroglobulinaemia. Leuk. Lymphoma34(3–4), 373–379 (1999).
   PubMed Web of Science ®Google Scholar
• Hamblin TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin. Oncol.33(2), 230–239 (2006).
   PubMed Web of Science ®Google Scholar
• Robak E, Robak T. Skin lesions in chronic lymphocytic leukemia. Leuk. Lymphoma48(5), 855–865 (2007).
   PubMed Web of Science ®Google Scholar
• Granel B, Bouabdallah R, Serratrice J et al. Prelymphomatous presentation of T-cell non-Hodgkin lymphomas. A clinical and histopathological study of 11 cases. Eur. J. Intern. Med.12(1), 57–59 (2001).
   PubMedGoogle Scholar
• Siegert W, Nerl C, Agthe A et al. Angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma: prognostic impact of clinical observations and laboratory findings at presentation. The Kiel Lymphoma Study Group. Ann. Oncol.6(7), 659–664 (1995).
   PubMed Web of Science ®Google Scholar
• Freter CE, Cossman J. Angioimmunoblastic lymphadenopathy with dysproteinemia. Semin. Oncol.20(6), 627–635 (1993).
   PubMed Web of Science ®Google Scholar
• Dellagi K, Brouet JC, Seligmann M. Antivimentin autoantibodies in angioimmunoblastic lymphadenopathy. N. Engl. J. Med.310(4), 215–218 (1984).
   PubMed Web of Science ®Google Scholar
• Belhadj K, Reyes F, Farcet JP et al. Hepatosplenic gd T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood102(13), 4261–4269 (2003).
   PubMed Web of Science ®Google Scholar
• Motta G, Vianello F, Menin C et al. Hepatosplenic gd T-cell lymphoma presenting with immune-mediated thrombocytopenia and hemolytic anemia (Evans’ syndrome). Am. J. Hematol.69(4), 272–276 (2002).
   PubMed Web of Science ®Google Scholar
• Tilly H, Gaulard P, Lepage E et al. Primary anaplastic large-cell lymphoma in adults: clinical presentation, immunophenotype, and outcome. Blood90(9), 3727–3734 (1997).
   PubMed Web of Science ®Google Scholar
• Pulford K, Falini B, Banham AH et al. Immune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma. Blood96(4), 1605–1607 (2000).
   PubMed Web of Science ®Google Scholar
• Pers JO, Jamin C, Predine-Hug F, Lydyard P, Youinou P. The role of CD5-expressing B cells in health and disease (review). Int. J. Mol. Med.3(3), 239–245 (1999).
   PubMed Web of Science ®Google Scholar
• Dighiero G. Autoimmunity and B-cell malignancies. Hematol. Cell Ther.40(1), 1–9 (1998).
   PubMedGoogle Scholar
• Yumoto N, Kurosu K, Furukawa M, Mikata A. CDR3 sequences of MALT lymphoma show homology with those of autoreactive B-cell lines. Jpn. J. Cancer Res.90(8), 849–857 (1999).
   PubMedGoogle Scholar
• Stevenson FK, Spellerberg MB, Chapman CJ, Hamblin TJ. Differential usage of an autoantibody-associated VH gene, VH4–21, by human B-cell tumors. Leuk. Lymphoma16(5–6), 379–384 (1995).
   PubMed Web of Science ®Google Scholar
• Stevenson FK, Spellerberg MB, Treasure J et al. Differential usage of an Ig heavy chain variable region gene by human B-cell tumors. Blood82(1), 224–230 (1993).
   PubMed Web of Science ®Google Scholar
• Rettig MB, Vescio RA, Cao J et al.VH gene usage is multiple myeloma: complete absence of the VH4–21 (VH4–34) gene. Blood87(7), 2846–2852 (1996).
   PubMed Web of Science ®Google Scholar
• Musette P, Joly P, Gilbert D et al. A paraneoplastic mixed bullous skin disease: breakdown in tolerance to multiple epidermal antigens. Br. J. Dermatol.143(1), 149–153 (2000).
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE, Ansell SM. Attenuation of CD8+ T-cell function by CD4+ CD25+ regulatory T cells in B-cell non-Hodgkin’s lymphoma. Cancer Res.66(20), 10145–10152 (2006).
   PubMed Web of Science ®Google Scholar
• Mackay IR, Rose NR. Autoimmunity and lymphoma: tribulations of B cells. Nat. Immunol.2(9), 793–795 (2001).
   PubMed Web of Science ®Google Scholar
• Mele A, Pulsoni A, Bianco E et al. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case–control study. Blood102(3), 996–999 (2003).
   PubMed Web of Science ®Google Scholar
• Chan CH, Hadlock KG, Foung SK, Levy S. V(H)1–69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood97(4), 1023–1026 (2001).
   PubMed Web of Science ®Google Scholar
• Quinn ER, Chan CH, Hadlock KG et al. The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood98(13), 3745–3749 (2001).
   PubMed Web of Science ®Google Scholar
• Curry MP, Golden-Mason L, Doherty DG et al. Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver. J. Hepatol.38(5), 642–650 (2003).
   PubMed Web of Science ®Google Scholar
• Rieux-Laucat F, Blachere S, Danielan S et al. Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations. Blood94(8), 2575–2582 (1999).
   PubMed Web of Science ®Google Scholar
• Straus SE, Jaffe ES, Puck JM et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood98(1), 194–200 (2001).
   PubMed Web of Science ®Google Scholar
• Boulanger E, Rieux-Laucat F, Picard C et al. Diffuse large B-cell non-Hodgkin’s lymphoma in a patient with autoimmune lymphoproliferative syndrome. Br. J. Haematol.113(2), 432–434 (2001).
   PubMed Web of Science ®Google Scholar
• Poppema S, Maggio E, van den Berg A. Development of lymphoma in autoimmune lymphoproliferative syndrome (ALPS) and its relationship to Fas gene mutations. Leuk. Lymphoma45(3), 423–431 (2004).
   PubMed Web of Science ®Google Scholar
• Gronbaek K, Straten PT, Ralfkiaer E et al. Somatic Fas mutations in non-Hodgkin’s lymphoma: association with extranodal disease and autoimmunity. Blood92(9), 3018–3024 (1998).
   PubMed Web of Science ®Google Scholar
• Schattner EJ, Friedman SM, Casali P. Inhibition of Fas-mediated apoptosis by antigen: implications for lymphomagenesis. Autoimmunity35(4), 283–289 (2002).
   PubMed Web of Science ®Google Scholar
• Murayama T, Imoto S, Takahashi T et al. Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia with cyclosporin A. Cancer69(10), 2567–2570 (1992).
   PubMed Web of Science ®Google Scholar
• Somer BG, Tsai DE, Downs L, Weinstein B, Schuster SJ. Improvement in Sjogren’s syndrome following therapy with rituximab for marginal zone lymphoma. Arthritis Rheum.49(3), 394–398 (2003).
   PubMed Web of Science ®Google Scholar
• Looney RJ. B cells as a therapeutic target in autoimmune diseases other than rheumatoid arthritis. Rheumatology (Oxford)44(Suppl. 2), ii13–ii17 (2005).
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood101(10), 3827–3834 (2003).
   PubMed Web of Science ®Google Scholar
• Cervetti G, Mechelli S, Riccioni R et al. High efficacy of rituximab in indolent HCV-related lymphoproliferative disorders associated with systemic autoimmune diseases. Clin. Exp. Rheumatol.23(6), 877–880 (2005).
   PubMed Web of Science ®Google Scholar
• Layios N, Van Den Neste E, Jost E et al. Remission of severe cold agglutinin disease after rituximab therapy. Leukemia15(1), 187–188 (2001).
   PubMed Web of Science ®Google Scholar
• Bauduer F. Rituximab: a very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD20-positive, low-grade non-Hodgkin’s lymphoma. Br. J. Haematol.112(4), 1085–1086 (2001).
   PubMed Web of Science ®Google Scholar
• Robak T. Monoclonal antibodies in the treatment of autoimmune cytopenias. Eur. J. Haematol.72(2), 79–88 (2004).
   PubMed Web of Science ®Google Scholar
• Kuwana M, Nomura S, Fujimura K et al. Effect of a single injection of humanized anti-CD154 monoclonal antibody on the platelet-specific autoimmune response in patients with immune thrombocytopenic purpura. Blood103(4), 1229–1236 (2004).
   PubMed Web of Science ®Google Scholar
• Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J. Clin. Immunol.27(1), 1–18 (2007).
   PubMed Web of Science ®Google Scholar
• Rathmell JC, Elstrom RL, Cinalli RM, Thompson CB. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol.33(8), 2223–2232 (2003).
   PubMed Web of Science ®Google Scholar
• Blaes F, Klotz M, Huwer H et al. Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer. Ann. Thorac. Surg.69(1), 254–258 (2000).
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Charalambopoulos A, Pliarchopoulou K et al. The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma. Anticancer Res.20(6B), 4351–4353 (2000).
   PubMed Web of Science ®Google Scholar
• Iakoubov LZ, Torchilin VP. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect. Prev.22(5), 470–475 (1998).
   PubMedGoogle Scholar
• Iakoubov LZ, Torchilin VP. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res.9(8), 439–446 (1997).
   PubMed Web of Science ®Google Scholar
• Torchilin VP, Iakoubov LZ, Estrov Z. Antinuclear autoantibodies as potential antineoplastic agents. Trends Immunol.22(8), 424–427 (2001).
   PubMed Web of Science ®Google Scholar
• Bencimon C, Salles G, Moreira A et al. Prevalence of anticentromere F protein autoantibodies in 347 patients with non-Hodgkin’s lymphoma. Ann. NY Acad. Sci.1050, 319–326 (2005).
   PubMed Web of Science ®Google Scholar